Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker alleged that Hims & Hers marketed unauthorized versions of semaglutide, the active…
GLP-1s
Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, including the new 12.5 mg and…
Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg reported June 10. Eli Lilly CFO Lucas Montarce…
A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four takeaways:
New prescriptions for Wegovy among teenagers increased by 50% between 2023 and 2024, according to a June 3 report from healthcare data company Truveta. To analyze GLP-1 utilization trends among adolescents, Truveta examined data from 1.2 million children aged 12…
Advertisement
Over the past month, studies have shown Zepbound leads to more weight loss than Wegovy, and GLP-1 drugs may lower obesity-related cancer risk better than bariatric surgery. Here are eight quick updates on the medication class: 1. The percentage of…
In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records. Fair Health also found that, over those…
An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal reported May 18. After the FDA declared the yearslong shortages of Novo…
A blockbuster drug class that includes Ozempic, Wegovy and Trulicity is pioneering avenues in the healthcare industry and redefining obesity care as the weight loss therapy market stretches toward $100 billion.
A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the drugs’ ability to reduce inflammation. The findings, published May 11…